|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCB11 protein] |
CTD |
PMID:24306262 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects transport multiple interactions |
ISO |
ABCC1 protein affects the transport of Bilirubin Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Bilirubin inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Glutathione promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; verlukast inhibits the reaction [ABCC1 protein affects the transport of Bilirubin] |
CTD |
PMID:15245331 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity multiple interactions affects transport |
EXP |
Bilirubin results in decreased activity of ABCC2 protein Bilirubin analog inhibits the reaction [tert-Butylhydroperoxide affects the localization of and results in decreased activity of ABCC2 protein] ABCC2 protein affects the transport of Bilirubin |
CTD |
PMID:15374814 PMID:15901347 PMID:24306262 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[[Bilirubin binds to and results in increased activity of AHR protein] which binds to CYP1A promoter] which results in increased expression of CYP1A mRNA |
CTD |
PMID:18187559 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Bilirubin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression multiple interactions |
ISO EXP |
Bilirubin results in decreased expression of ALAD mRNA Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of ALAD protein] |
CTD |
PMID:12853123 PMID:20196124 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of ALAS1 protein] |
CTD |
PMID:12853123 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO EXP |
ALB protein binds to Bilirubin; Bilirubin binds to ALB protein Folic Acid inhibits the reaction [Homocysteine inhibits the reaction [ALB protein binds to Bilirubin]]; Folic Acid inhibits the reaction [phenylhydrazine inhibits the reaction [ALB protein binds to Bilirubin]]; Homocysteine inhibits the reaction [ALB protein binds to Bilirubin]; phenylhydrazine inhibits the reaction [ALB protein binds to Bilirubin] [homocysteine thiolactone results in increased metabolism of ALB protein] affects the reaction [ALB protein binds to Bilirubin]; Sulfisoxazole inhibits the reaction [Bilirubin binds to ALB protein] |
CTD |
PMID:21280114 PMID:33788065 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ANXA1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Bilirubin results in increased expression of AREG mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028
|
|
G |
Asb13 |
ankyrin repeat and SOCS box-containing 13 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ASB13 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr17:66,564,653...66,583,365
Ensembl chr17:66,562,434...66,583,337
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Bilirubin results in increased expression of ATF3 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression multiple interactions |
ISO |
Bilirubin results in increased expression of ATF6 mRNA 4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of ATF6 mRNA] |
CTD |
PMID:27578021 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ATP1A1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Axin2 |
axin 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of AXIN2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
Bilirubin promotes the reaction [Iron-Dextran Complex results in increased expression of BCL2L1 protein] |
CTD |
PMID:20709802 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bloc1s1 |
biogenesis of lysosomal organelles complex-1, subunit 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of BLOC1S1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:1,347,495...1,351,103
Ensembl chr 7:1,340,934...1,351,558
|
|
G |
C1d |
C1D nuclear receptor corepressor |
decreases expression |
ISO |
Bilirubin results in decreased expression of C1D mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:91,660,951...91,673,177
Ensembl chr14:91,660,989...91,672,852
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased cleavage of CASP3 protein]; Bilirubin inhibits the reaction [Iron-Dextran Complex results in increased activity of CASP3 protein]; CYP2A5 protein inhibits the reaction [Bilirubin results in increased cleavage of CASP3 protein] Bilirubin results in increased activity of CASP3 protein |
CTD |
PMID:20709802 PMID:23628428 PMID:27578021 PMID:28805483 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
ISO EXP |
Bilirubin results in decreased expression of CAT mRNA Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of CAT protein] |
CTD |
PMID:12853123 PMID:20196124 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
Bilirubin results in decreased expression of CCDC80 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of CCND1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd302 |
CD302 molecule |
decreases expression |
ISO |
Bilirubin results in decreased expression of CD302 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:44,722,324...44,756,045
Ensembl chr 3:44,722,325...44,756,045
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Bilirubin results in increased expression of CHAC1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chka |
choline kinase alpha |
increases expression |
ISO |
Bilirubin results in increased expression of CHKA mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Clcc1 |
chloride channel CLIC-like 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of CLCC1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:196,296,350...196,326,914
Ensembl chr 2:196,296,393...196,326,913
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of CLIP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Bilirubin results in decreased expression of COL3A1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
decreases expression |
ISO |
Bilirubin results in decreased expression of COX15 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:242,605,588...242,622,279
Ensembl chr 1:242,605,588...242,622,261
|
|
G |
Cpd |
carboxypeptidase D |
decreases expression |
ISO |
Bilirubin results in decreased expression of CPD mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:61,623,528...61,687,491
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Bilirubin results in increased expression of CSF2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctsh |
cathepsin H |
decreases expression |
ISO |
Bilirubin results in decreased expression of CTSH mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Bilirubin results in increased expression of CXCL10 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Bilirubin results in increased expression of CXCL11 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Bilirubin results in increased expression of CXCL2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
Bilirubin results in increased expression of CYP1A1 mRNA; Bilirubin results in increased expression of CYP1A1 protein |
CTD |
PMID:20196124 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Bilirubin results in decreased activity of CYP1A2 protein |
CTD |
PMID:16183037 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
Bilirubin results in increased expression of CYP2B6 mRNA IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:15382119 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO EXP |
Bilirubin results in increased expression of CYP3A4 mRNA [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Bilirubin IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:15382119 PMID:34461081 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Bilirubin |
CTD |
PMID:34461081 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases activity |
EXP |
[Manganese co-treated with Bilirubin] results in decreased activity of CYP7A1 protein Bilirubin results in decreased activity of CYP7A1 protein |
CTD |
PMID:12700418 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Bilirubin results in increased expression of DDIT3 mRNA Bilirubin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of DDIT3 mRNA]; [Bilirubin co-treated with Rotenone] promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of DDIT3 mRNA] |
CTD |
PMID:20196124 PMID:27578021 PMID:32033040 PMID:37054934 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
decreases expression |
ISO |
Bilirubin results in decreased expression of DEPTOR mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dmkn |
dermokine |
decreases expression |
ISO |
Bilirubin results in decreased expression of DMKN mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:86,013,237...86,031,243
Ensembl chr 1:86,014,188...86,030,006
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression |
ISO |
Bilirubin affects the expression of DNAJB1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnpep |
aspartyl aminopeptidase |
decreases expression |
ISO |
Bilirubin results in decreased expression of DNPEP mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 9:76,799,931...76,808,841
Ensembl chr 9:76,783,966...76,808,716
|
|
G |
Dpy19l1 |
dpy-19 like C-mannosyltransferase 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of DPY19L1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
ISO |
Bilirubin results in increased expression of DUSP5 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Bilirubin inhibits the reaction [cobaltous chloride results in increased expression of EDN1 mRNA]; Bilirubin inhibits the reaction [cobaltous chloride results in increased secretion of EDN1 protein] |
CTD |
PMID:27297870 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of EGLN1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
decreases expression |
ISO |
Bilirubin results in decreased expression of EI24 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eid1 |
EP300 interacting inhibitor of differentiation 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of EID1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:112,922,961...112,924,680
Ensembl chr 3:112,922,668...112,924,752
|
|
G |
Eif2ak1 |
eukaryotic translation initiation factor 2 alpha kinase 1 |
multiple interactions |
ISO |
[lead nitrate co-treated with EIF2AK1 gene mutant form] results in increased abundance of Bilirubin |
CTD |
PMID:25411909 |
|
NCBI chr12:10,710,771...10,744,597
Ensembl chr12:10,705,874...10,744,573
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Bilirubin results in increased phosphorylation of and results in increased activity of EIF2AK3 protein; EIF2AK3 mRNA promotes the reaction [Bilirubin results in increased expression of CXCL8 mRNA] |
CTD |
PMID:20196124 PMID:27578021 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
Bilirubin results in increased phosphorylation of and results in increased activity of EIF2S1 protein |
CTD |
PMID:20196124 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Endod1 |
endonuclease domain containing 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ENDOD1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Fam174a |
family with sequence similarity 174, member A |
decreases expression |
ISO |
Bilirubin results in decreased expression of FAM174A mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 9:95,742,815...95,761,083
Ensembl chr 9:95,742,927...95,761,081
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases abundance |
ISO |
FGF15 gene mutant form results in increased abundance of Bilirubin |
CTD |
PMID:24699334 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Bilirubin inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein] |
CTD |
PMID:25371888 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Bilirubin results in increased expression of FOSL1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Bilirubin results in increased expression of GADD45B mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gas5 |
growth arrest specific 5 |
decreases expression |
ISO |
Bilirubin results in decreased expression of GAS5 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of GPX1 protein] |
CTD |
PMID:12853123 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsn |
gelsolin |
decreases expression |
ISO |
Bilirubin results in decreased expression of GSN mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression multiple interactions |
ISO |
Bilirubin results in increased expression of GSTA1 mRNA IL1B protein inhibits the reaction [Bilirubin results in increased expression of GSTA1 mRNA] |
CTD |
PMID:15382119 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression affects binding multiple interactions |
ISO EXP |
Bilirubin results in increased expression of GSTA2 mRNA Bilirubin binds to GSTA2 protein IL1B protein inhibits the reaction [Bilirubin results in increased expression of GSTA2 mRNA] |
CTD |
PMID:1148165 PMID:2768223 PMID:15382119 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of GSTA4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of GSTM1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of GSTP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
H1f4 |
H1.4 linker histone, cluster member |
increases expression |
ISO |
Bilirubin results in increased expression of H1-4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403
|
|
G |
H2ac25 |
H2A clustered histone 25 |
increases expression |
ISO |
Bilirubin results in increased expression of H2AC25 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
Hacd4 |
3-hydroxyacyl-CoA dehydratase 4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of HACD4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:102,887,597...102,915,376
Ensembl chr 5:102,887,588...102,915,338
|
|
G |
Heph |
hephaestin |
decreases expression |
ISO |
Bilirubin results in decreased expression of HEPH mRNA |
CTD |
PMID:20196124 |
|
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Bilirubin results in increased expression of HERPUD1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Bilirubin inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; Bilirubin inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] |
CTD |
PMID:27297870 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
increases expression |
ISO |
Bilirubin results in increased expression of H4C9 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[Manganese co-treated with Bilirubin] results in decreased activity of HMGCR protein |
CTD |
PMID:12700418 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases chemical synthesis increases expression affects activity increases abundance |
EXP ISO |
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased abundance of Bilirubin; Bilirubin inhibits the reaction [Aminolevulinic Acid results in increased activity of HMOX1 protein] HMOX1 protein results in increased chemical synthesis of Bilirubin [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; sodium arsenite promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin] Bilirubin results in increased expression of HMOX1 mRNA Bilirubin affects the activity of HMOX1 protein [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Bilirubin; Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Bilirubin inhibits the reaction [[tin protoporphyrin IX results in decreased activity of HMOX1 protein] which results in increased chemical synthesis of Reactive Oxygen Species]; Bilirubin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Lopinavir promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin] HMOX1 protein results in increased abundance of Bilirubin |
CTD |
PMID:12690112 PMID:12853123 PMID:15226216 PMID:15602829 PMID:20196124 PMID:21401295 PMID:22688006 PMID:26968795 PMID:32033040 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects abundance |
ISO |
HMOX2 affects the abundance of Bilirubin |
CTD |
PMID:16181104 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO EXP |
Bilirubin results in increased expression of HSPA5 mRNA; Bilirubin results in increased expression of HSPA5 protein Bilirubin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of HSPA5 mRNA] 4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of HSPA5 mRNA]; Bilirubin inhibits the reaction [[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA] |
CTD |
PMID:20196124 PMID:27578021 PMID:32033040 PMID:37054934 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of IDH2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
increases expression |
ISO |
Bilirubin results in increased expression of IFRD1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
ISO |
Bilirubin results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Bilirubin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Bilirubin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] Bilirubin results in decreased susceptibility to IL18 protein |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP2B6 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP2C9 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of CYP3A4 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of GSTA1 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of GSTA2 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of SLCO1B1 mRNA]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of UGT1A1 mRNA] Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA] |
CTD |
PMID:15382119 PMID:18206168 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Bilirubin results in increased expression of IL6 mRNA [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA] |
CTD |
PMID:20196124 PMID:32033040 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kl |
Klotho |
decreases expression |
EXP |
Bilirubin results in decreased expression of KL mRNA; Bilirubin results in decreased expression of KL protein |
CTD |
PMID:28805483 |
|
NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
|
|
G |
Lamb1 |
laminin subunit beta 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of LAMB1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of LAMP2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Leprot |
leptin receptor overlapping transcript |
decreases expression |
ISO |
Bilirubin results in decreased expression of LEPROT mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:116,289,843...116,301,951
Ensembl chr 5:116,289,822...116,301,988
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Bilirubin results in increased expression of LIF mRNA |
CTD |
PMID:20196124 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of LRP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Ly6al1 |
lymphocyte antigen 6 complex, locus A like 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of LY6A mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:107,011,585...107,018,125
Ensembl chr 7:107,011,623...107,015,179
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
Bilirubin results in decreased expression of MAF mRNA |
CTD |
PMID:20196124 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
Bilirubin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:12690112 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
Bilirubin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:12690112 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapre2 |
microtubule-associated protein, RP/EB family, member 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of MAPRE2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr18:15,028,675...15,169,553
Ensembl chr18:15,029,041...15,168,044
|
|
G |
Me2 |
malic enzyme 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ME2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
|
|
G |
Megf9 |
multiple EGF-like-domains 9 |
decreases expression |
ISO |
Bilirubin results in decreased expression of MEGF9 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:83,993,565...84,105,622
Ensembl chr 5:83,993,565...84,105,622
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases secretion |
ISO |
MET gene mutant form results in increased secretion of Bilirubin |
CTD |
PMID:27394961 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of MGST2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Bilirubin results in increased expression of MMP13 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of MPZL2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298
|
|
G |
Mrpl18 |
mitochondrial ribosomal protein L18 |
decreases expression |
ISO |
Bilirubin results in decreased expression of MRPL18 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:47,837,169...47,841,987
Ensembl chr 1:47,836,561...47,841,987
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO |
Bilirubin affects the localization of NFE2L2 protein Bilirubin promotes the reaction [NFE2L2 protein results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:23628428 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:37054934 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nid1 |
nidogen 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of NID1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr17:86,085,133...86,158,272
Ensembl chr17:86,085,077...86,158,267
|
|
G |
Nnt |
nicotinamide nucleotide transhydrogenase |
decreases expression |
ISO |
Bilirubin results in decreased expression of NNT mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823
|
|
G |
Noct |
nocturnin |
increases expression |
ISO |
Bilirubin results in increased expression of NOCT mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] |
CTD |
PMID:18206168 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression affects abundance affects transport |
ISO |
Bilirubin results in increased expression of NR1I2 mRNA NR1I2 protein affects the abundance of Bilirubin NR1I2 protein affects the transport of Bilirubin |
CTD |
PMID:15726644 PMID:18706437 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
Bilirubin results in increased expression of NR1I3 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO |
Bilirubin results in increased expression of OSGIN1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions |
ISO |
Bilirubin results in increased expression of PARP1 protein modified form 4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of PARP1 protein modified form] |
CTD |
PMID:27578021 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PDK1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PGAP2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114
|
|
G |
Phb1 |
prohibitin 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PHB1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PIAS1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pla1a |
phospholipase A1 member A |
decreases expression |
ISO |
Bilirubin results in decreased expression of PLA1A mRNA |
CTD |
PMID:20196124 |
|
NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PMP22 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pon2 |
paraoxonase 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PON2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Prdx4 |
peroxiredoxin 4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of PRDX4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Bilirubin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rassf4 |
Ras association domain family member 4 |
increases expression |
ISO |
Bilirubin results in increased expression of RASSF4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
ISO |
Bilirubin results in decreased expression of RBM39 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Rbm5 |
RNA binding motif protein 5 |
decreases expression |
ISO |
Bilirubin results in decreased expression of RBM5 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:108,420,220...108,449,481
Ensembl chr 8:108,420,222...108,449,430
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Bilirubin results in increased expression of RELA mRNA |
CTD |
PMID:27578021 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhobtb3 |
Rho-related BTB domain containing 3 |
decreases expression |
ISO |
Bilirubin results in decreased expression of RHOBTB3 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041
|
|
G |
Rnase4 |
ribonuclease A family member 4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of RNASE4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr15:24,312,765...24,330,112
Ensembl chr15:24,312,464...24,330,117
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
decreases expression |
ISO |
Bilirubin results in decreased expression of S100A10 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of S100A4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
Scp2 |
sterol carrier protein 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SCP2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb1a |
serpin family B member 1A |
decreases expression |
ISO |
Bilirubin results in decreased expression of SERPINB1A mRNA |
CTD |
PMID:20196124 |
|
NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Bilirubin results in increased expression of SERPINE1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SESN1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Sgpp1 |
sphingosine-1-phosphate phosphatase 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SGPP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 6:94,425,339...94,446,534
Ensembl chr 6:94,425,339...94,446,534
|
|
G |
Slc16a12 |
solute carrier family 16, member 12 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SLC16A12 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141
|
|
G |
Slc23a1 |
solute carrier family 23 member 1 |
increases expression |
ISO |
Bilirubin results in increased expression of SLC23A1 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
ISO |
Bilirubin results in increased expression of SLC23A2 mRNA |
CTD |
PMID:18706437 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions increases expression |
ISO |
[[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione] which results in decreased susceptibility to Hydrogen Peroxide; [[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione; [Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine; Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein] Bilirubin results in increased expression of SLC3A2 mRNA |
CTD |
PMID:22216172 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions increases expression |
ISO |
[[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione] which results in decreased susceptibility to Hydrogen Peroxide; [[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione; [Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine; Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein] Bilirubin results in increased expression of SLC7A11 mRNA |
CTD |
PMID:22216172 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Snx14 |
sorting nexin 14 |
decreases expression |
ISO |
Bilirubin results in decreased expression of SNX14 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:89,283,673...89,390,597
Ensembl chr 8:89,298,114...89,390,580
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Aminolevulinic Acid results in decreased activity of SOD1 protein] |
CTD |
PMID:12853123 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sost |
sclerostin |
decreases expression |
ISO |
Bilirubin results in decreased expression of SOST mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:86,912,517...86,915,561
Ensembl chr10:86,911,517...86,915,561
|
|
G |
Sp5 |
Sp5 transcription factor |
decreases expression |
ISO |
Bilirubin results in decreased expression of SP5 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 3:55,274,931...55,277,733
Ensembl chr 3:55,274,931...55,277,733
|
|
G |
Tapbp |
TAP binding protein |
decreases expression |
ISO |
Bilirubin results in decreased expression of TAPBP mRNA |
CTD |
PMID:20196124 |
|
NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181
|
|
G |
Tcf4 |
transcription factor 4 |
decreases expression |
ISO |
Bilirubin results in decreased expression of TCF4 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tet1 |
tet methylcytosine dioxygenase 1 |
decreases expression |
EXP |
Bilirubin results in decreased expression of TET1 mRNA; Bilirubin results in decreased expression of TET1 protein |
CTD |
PMID:28805483 |
|
NCBI chr20:25,761,042...25,840,926
Ensembl chr20:25,768,120...25,833,052
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
Bilirubin results in increased expression of TIPARP mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of TM9SF2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr15:99,201,556...99,254,054
Ensembl chr15:99,201,489...99,254,049
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of TNF mRNA] Bilirubin results in increased expression of TNF mRNA; Bilirubin results in increased expression of TNF protein |
CTD |
PMID:27578021 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf19 |
TNF receptor superfamily member 19 |
decreases expression |
ISO |
Bilirubin results in decreased expression of TNFRSF19 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795
|
|
G |
Tpp1 |
tripeptidyl peptidase 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of TPP1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:160,097,984...160,104,108
Ensembl chr 1:160,096,833...160,104,129
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
decreases expression |
ISO |
Bilirubin results in decreased expression of TRIB2 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
decreases expression |
ISO |
Bilirubin results in decreased expression of UBE2I mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression increases glucuronidation multiple interactions increases metabolic processing decreases glucuronidation decreases activity |
ISO EXP |
Bilirubin results in increased expression of UGT1A1 mRNA UGT1A1 protein results in increased glucuronidation of Bilirubin 5-methoxypsoralen promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; chrysin promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; Coumarins analog promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; imperatorin promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin] UGT1A1 protein results in increased metabolism of Bilirubin UGT1A1 protein results in increased glucuronidation of Bilirubin; UGT1A1 results in increased glucuronidation of Bilirubin UGT1A1 gene mutant form results in decreased glucuronidation of Bilirubin 5-methoxypsoralen promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; chrysin promotes the reaction [UGT1A1 protein affects the glucuronidation of Bilirubin]; chrysin promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; Coumarins analog promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; IL1B protein inhibits the reaction [Bilirubin results in increased expression of UGT1A1 mRNA]; imperatorin promotes the reaction [UGT1A1 protein results in increased glucuronidation of Bilirubin]; UGT1A1 protein results in increased glucuronidation of and results in decreased activity of Bilirubin Bilirubin results in decreased activity of UGT1A1 protein |
CTD |
PMID:10950852 PMID:12153725 PMID:15334623 PMID:15382119 PMID:15557560 PMID:15921999 PMID:15988124 PMID:17599282 PMID:17898154 PMID:23401472 PMID:25370011 PMID:27060662 More...
|
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity |
ISO |
Bilirubin results in decreased activity of UGT1A3 protein |
CTD |
PMID:15334623 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Uqcr11 |
ubiquinol-cytochrome c reductase, complex III subunit XI |
decreases expression |
ISO |
Bilirubin results in decreased expression of UQCR11 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:9,305,042...9,309,753
Ensembl chr 7:9,305,058...9,309,750
|
|
G |
Uqcrb |
ubiquinol-cytochrome c reductase binding protein |
decreases expression |
ISO |
Bilirubin results in decreased expression of UQCRB mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of UQCRC1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
decreases expression |
ISO |
Bilirubin results in decreased expression of UQCRH mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
decreases expression |
ISO |
Bilirubin results in decreased expression of UXS1 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334
|
|
G |
Vldlr |
very low density lipoprotein receptor |
decreases expression |
ISO |
Bilirubin results in decreased expression of VLDLR mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
ISO |
[VWF protein affects the susceptibility to 1-Naphthylisothiocyanate] which affects the abundance of Bilirubin |
CTD |
PMID:34619301 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression multiple interactions |
ISO EXP |
Bilirubin results in increased expression of XBP1 mRNA Bilirubin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of XBP1 mRNA alternative form] 4-phenylbutyric acid inhibits the reaction [Bilirubin results in increased expression of XBP1 mRNA] |
CTD |
PMID:27578021 PMID:37054934 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ZBTB20 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr11:57,052,129...57,791,214
Ensembl chr11:57,072,880...57,510,210
|
|
G |
Zbtb8os |
zinc finger and BTB domain containing 8 opposite strand |
decreases expression |
ISO |
Bilirubin results in decreased expression of ZBTB8OS mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:141,675,595...141,687,148
Ensembl chr 5:141,675,857...141,688,660
|
|
G |
Zcchc7 |
zinc finger CCHC-type containing 7 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ZCCHC7 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300
|
|
G |
Zfand2a |
zinc finger AN1-type containing 2A |
increases expression |
ISO |
Bilirubin results in increased expression of ZFAND2A mRNA |
CTD |
PMID:20196124 |
|
NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
|
|
G |
Zfp207 |
zinc finger protein 207 |
decreases expression |
ISO |
Bilirubin results in decreased expression of ZFP207 mRNA |
CTD |
PMID:20196124 |
|
NCBI chr10:65,385,807...65,398,086
Ensembl chr10:65,385,740...65,397,386
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Biliverdine inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein] |
CTD |
PMID:15486963 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[cobaltiprotoporphyrin results in increased activity of HMOX1 protein] which results in increased chemical synthesis of Biliverdine |
CTD |
PMID:26224716 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein] |
CTD |
PMID:15486963 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein] |
CTD |
PMID:15486963 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Biliverdine inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Biliverdine inhibits the reaction [IL18 protein results in increased expression of PTEN protein] Biliverdine results in decreased susceptibility to IL18 protein |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] |
CTD |
PMID:15486963 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Biliverdine inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein] |
CTD |
PMID:15486963 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
cobamamide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
|
G |
Cpox |
coproporphyrinogen oxidase |
decreases carboxylation multiple interactions |
ISO |
CPOX protein results in decreased carboxylation of coproporphyrinogen III Mercury inhibits the reaction [CPOX protein results in decreased carboxylation of coproporphyrinogen III] |
CTD |
PMID:19339664 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Vitamin B 12 results in decreased expression of ABCB1 mRNA; Vitamin B 12 results in decreased expression of ABCB1 protein Vitamin B 12 inhibits the reaction [Methotrexate results in increased expression of ABCB1 mRNA] |
CTD |
PMID:17982279 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcd4 |
ATP binding cassette subfamily D member 4 |
affects metabolic processing |
ISO |
ABCD4 protein affects the metabolism of Vitamin B 12 |
CTD |
PMID:22922874 |
|
NCBI chr 6:104,246,459...104,260,965
Ensembl chr 6:104,246,468...104,280,276
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Vitamin B 12 inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA] |
CTD |
PMID:18239293 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions |
ISO |
Folic Acid promotes the reaction [Vitamin B 12 promotes the reaction [AS3MT protein results in increased methylation of Arsenic]]; Vitamin B 12 promotes the reaction [AS3MT protein results in increased methylation of Arsenic] |
CTD |
PMID:20049124 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of BDNF protein] |
CTD |
PMID:38049026 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Folic Acid inhibits the reaction [Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP3 mRNA]]; Vitamin B 12 inhibits the reaction [Streptozocin results in increased cleavage of CASP3 protein]; Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP3 mRNA] |
CTD |
PMID:23935743 PMID:38049026 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
Folic Acid inhibits the reaction [Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP8 mRNA]]; Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:23935743 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Vitamin B 12 promotes the reaction [Folic Acid inhibits the reaction [arsenic trioxide results in decreased activity of CAT protein]] |
CTD |
PMID:16214333 PMID:20118189 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA; [Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA |
CTD |
PMID:25003120 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
[Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of CD40 mRNA |
CTD |
PMID:30116142 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein; [Vitamin E co-treated with Ascorbic Acid co-treated with Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein |
CTD |
PMID:16517955 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:20118189 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of DDIT3 protein] Vitamin B 12 inhibits the reaction [Streptozocin results in increased expression of DDIT3 protein] |
CTD |
PMID:37263574 PMID:38049026 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:38049026 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA; [Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS1 protein; Folic Acid inhibits the reaction [[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA]; Folic Acid promotes the reaction [[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS1 protein]; Vitamin B 12 deficiency promotes the reaction [Folic Acid results in increased activity of FADS1 protein] |
CTD |
PMID:22133376 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
EXP |
[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS2 protein; [Vitamin B 12 deficiency co-treated with Folic Acid] results in decreased activity of FADS2 protein; Folic Acid inhibits the reaction [[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS2 protein] |
CTD |
PMID:22133376 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Folh1 |
folate hydrolase 1 |
multiple interactions |
ISO |
Vitamin B 12 affects the reaction [FOLH1 gene SNP affects the susceptibility to and affects the metabolism of Arsenic] |
CTD |
PMID:29459232 |
|
NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379
|
|
G |
Fut2 |
fucosyltransferase 2 |
affects abundance |
ISO |
FUT2 gene polymorphism affects the abundance of Vitamin B 12 |
CTD |
PMID:18776911 |
|
NCBI chr 1:96,119,549...96,139,567
Ensembl chr 1:96,119,371...96,140,360
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of GDNF protein] |
CTD |
PMID:38049026 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in increased expression of GFAP protein] |
CTD |
PMID:38049026 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine promotes the reaction [Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine promotes the reaction [Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of HAVCR1 protein] |
CTD |
PMID:37263574 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
affects expression affects glycosylation |
ISO |
Vitamin B 12 affects the expression of HBA1 protein modified form Vitamin B 12 affects the glycosylation of HBA1 protein |
CTD |
PMID:2299304 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in decreased expression of HMOX1 protein] |
CTD |
PMID:37263574 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
Vitamin B 12 inhibits the reaction [Streptozocin results in increased expression of HSPA5 protein] [Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of HSPA5 protein] |
CTD |
PMID:37263574 PMID:38049026 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
increases methylation multiple interactions |
ISO |
Vitamin B 12 results in increased methylation of IL1B gene [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of IL1B mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased secretion of IL1B protein; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased methylation of IL1B gene |
CTD |
PMID:30116142 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [arsenic trioxide results in increased expression of IL6 protein] |
CTD |
PMID:16214333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Krt4 |
keratin 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Kynu |
kynureninase |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [Rotenone results in decreased expression of KYNU mRNA] |
CTD |
PMID:36553663 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrrc24 |
leucine rich repeat containing 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Vitamin B 12 results in decreased activity of MAOB protein |
CTD |
PMID:7430361 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of MAP2 protein] |
CTD |
PMID:38049026 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map4k1 |
mitogen activated protein kinase kinase kinase kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Vitamin B 12 inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:14566972 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA; Fatty Acids, Omega-3 promotes the reaction [[Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of MBP protein] |
CTD |
PMID:38049026 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
increases metabolic processing affects binding decreases metabolic processing |
ISO |
MMACHC protein results in increased metabolism of Vitamin B 12 Vitamin B 12 analog binds to MMACHC protein; Vitamin B 12 binds to MMACHC protein MMACHC protein mutant form results in decreased metabolism of Vitamin B 12 |
CTD |
PMID:19700356 |
|
NCBI chr 5:130,166,056...130,172,735
Ensembl chr 5:130,166,451...130,172,601
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
decreases expression multiple interactions |
EXP |
Vitamin B 12 deficiency results in decreased expression of MTHFR mRNA [Folic Acid co-treated with Vitamin B 12 deficiency] results in decreased expression of MTHFR mRNA; Fatty Acids, Omega-3 inhibits the reaction [Vitamin B 12 deficiency results in decreased expression of MTHFR mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
affects binding multiple interactions increases activity |
ISO EXP |
Vitamin B 12 binds to MTR protein [Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of MTR mRNA; Fatty Acids, Omega-3 promotes the reaction [Vitamin B 12 deficiency inhibits the reaction [Fatty Acids, Omega-3 results in increased expression of MTR mRNA]]; Vitamin B 12 deficiency inhibits the reaction [Fatty Acids, Omega-3 results in increased expression of MTR mRNA] Vitamin B 12 results in increased activity of MTR protein |
CTD |
PMID:17477549 PMID:17982279 PMID:25003120 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Mycl |
MYCL proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of NCF1 protein] |
CTD |
PMID:37263574 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in decreased expression of NFE2L2 protein] |
CTD |
PMID:37263574 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of NGF protein] |
CTD |
PMID:38049026 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
ISO |
Vitamin B 12 affects the reaction [bisphenol A affects the expression of NPY mRNA] |
CTD |
PMID:32960947 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Vitamin B 6 co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in decreased expression of NQO1 protein] |
CTD |
PMID:37263574 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA; Fatty Acids, Omega-3 inhibits the reaction [[Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013
|
|
G |
Per2 |
period circadian regulator 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein |
CTD |
PMID:20118189 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [Dietary Fats results in decreased expression of PPARG mRNA]; Vitamin B 12 inhibits the reaction [Dietary Fats results in decreased expression of PPARG mRNA] |
CTD |
PMID:23935743 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Prss8 |
serine protease 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815
|
|
G |
Rfx4 |
regulatory factor X4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases methylation |
ISO |
[Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SERPINE1 mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased methylation of SERPINE1 gene Vitamin B 12 results in increased methylation of SERPINE1 gene |
CTD |
PMID:30116142 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions |
ISO |
Vitamin B 12 inhibits the reaction [Dimethylnitrosamine results in increased expression of SERPINH1 mRNA] |
CTD |
PMID:18239293 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Slc25a30 |
solute carrier family 25, member 30 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Syp |
synaptophysin |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of SYP protein] |
CTD |
PMID:38049026 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tcn2 |
transcobalamin 2 |
multiple interactions |
ISO |
TCN2 protein binds to and results in increased uptake of Vitamin B 12 |
CTD |
PMID:14632784 |
|
NCBI chr14:78,813,343...78,828,549
Ensembl chr14:78,813,343...78,828,489
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
Vitamin B 12 inhibits the reaction [Streptozocin results in decreased expression of TH protein] |
CTD |
PMID:38049026 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [arsenic trioxide results in increased expression of TNF protein] [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of TNF mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased secretion of TNF protein |
CTD |
PMID:16214333 PMID:30116142 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression multiple interactions |
ISO |
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Heme binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:92,120,332...92,140,790
Ensembl chr 9:92,120,306...92,136,376
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:26,425,017...26,514,899
Ensembl chr 6:26,425,954...26,507,477
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA Heme results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:130,469,840...130,479,802
Ensembl chr 5:130,469,840...130,478,561
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases degradation increases metabolic processing decreases expression decreases abundance increases expression |
ISO EXP |
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Ly96 |
lymphocyte antigen 96 |
affects binding multiple interactions |
ISO |
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions increases secretion |
ISO |
SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK1 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36115635 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK8 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:85,727,989...85,731,523
Ensembl chr13:85,728,076...85,731,469
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Mt1 |
metallothionein 1 |
decreases response to substance multiple interactions |
ISO |
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases localization |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:121,433,993...121,439,158
Ensembl chr 5:121,434,096...121,439,154
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:88,313,837...88,366,182
Ensembl chr10:88,314,651...88,362,412
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,406,172...135,419,332
Ensembl chr 5:135,406,176...135,419,235
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization increases localization multiple interactions |
ISO |
Heme analog affects the localization of RELA protein Heme results in increased localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:130,026,255...130,031,127
Ensembl chr 7:130,026,341...130,030,248
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:106,746,642...106,768,182
Ensembl chr 3:106,656,742...106,768,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Smarcb1 |
SWI/SNF related BAF chromatin remodeling complex subunit B1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions affects binding |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] Heme binds to TLR4 protein |
CTD |
PMID:36115635 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:79,462,406...79,492,888
Ensembl chr16:79,462,402...79,492,693
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:56,286,604...56,345,160
Ensembl chr 5:56,286,725...56,345,513
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:79,185,563...79,191,657
Ensembl chr10:79,186,647...79,191,657
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
|
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[glutathionylcobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form |
CTD |
PMID:26989453 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions decreases expression |
ISO |
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:92,120,332...92,140,790
Ensembl chr 9:92,120,306...92,136,376
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:26,425,017...26,514,899
Ensembl chr 6:26,425,954...26,507,477
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression multiple interactions |
EXP |
Heme results in increased expression of FABP2 mRNA [Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:130,469,840...130,479,802
Ensembl chr 5:130,469,840...130,478,561
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions increases degradation decreases abundance increases metabolic processing increases expression |
ISO EXP |
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Heme results in increased expression of IL6 mRNA; Heme results in increased expression of IL6 protein LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:83,932,234...83,958,243
Ensembl chr13:83,948,124...83,958,227
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:84,384,790...84,394,125
Ensembl chr10:84,384,802...84,394,107
|
|
G |
Ly96 |
lymphocyte antigen 96 |
affects binding multiple interactions |
ISO |
Heme binds to LY96 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of IL6 protein]; LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein]; LY96 protein promotes the reaction [Heme results in increased localization of RELA protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein]; LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
Heme analog results in increased secretion of LYZ protein SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36115635 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Heme results in increased phosphorylation of MAPK3 protein LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
LY96 protein promotes the reaction [Heme results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36115635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:85,727,989...85,731,523
Ensembl chr13:85,728,076...85,731,469
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Mt1 |
metallothionein 1 |
decreases response to substance multiple interactions |
ISO |
MT1A protein results in decreased susceptibility to Heme [Heme co-treated with HPX protein] affects the activity of MT1 promoter |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases localization |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein LY96 protein promotes the reaction [Heme results in decreased localization of NFKBIA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:121,433,993...121,439,158
Ensembl chr 5:121,434,096...121,439,154
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:88,313,837...88,366,182
Ensembl chr10:88,314,651...88,362,412
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,406,172...135,419,332
Ensembl chr 5:135,406,176...135,419,235
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:71,310,387...71,396,752
Ensembl chr18:71,311,020...71,395,709
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization multiple interactions increases localization |
ISO |
Heme analog affects the localization of RELA protein LY96 protein promotes the reaction [Heme results in increased localization of RELA protein] |
CTD |
PMID:23355332 PMID:36115635 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:130,026,255...130,031,127
Ensembl chr 7:130,026,341...130,030,248
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:106,746,642...106,768,182
Ensembl chr 3:106,656,742...106,768,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Smarcb1 |
SWI/SNF related BAF chromatin remodeling complex subunit B1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tlr4 |
toll-like receptor 4 |
affects binding multiple interactions |
ISO |
Heme binds to TLR4 protein ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to LY96 protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Heme promotes the reaction [TLR4 protein binds to MYD88 protein]]; Heme promotes the reaction [TLR4 protein binds to LY96 protein]; Heme promotes the reaction [TLR4 protein binds to MYD88 protein] |
CTD |
PMID:36115635 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] LY96 protein promotes the reaction [Heme results in increased expression of TNF mRNA]; LY96 protein promotes the reaction [Heme results in increased expression of TNF protein] Heme results in increased expression of TNF mRNA; Heme results in increased expression of TNF protein Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 PMID:36115635 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:79,462,406...79,492,888
Ensembl chr16:79,462,402...79,492,693
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:56,286,604...56,345,160
Ensembl chr 5:56,286,725...56,345,513
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:79,185,563...79,191,657
Ensembl chr10:79,186,647...79,191,657
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:80,743,134...80,829,253
Ensembl chr11:80,743,134...80,829,208
|
|
|
G |
Aco1 |
aconitase 1 |
decreases activity |
EXP |
Hemin results in decreased activity of ACO1 protein |
CTD |
PMID:16568477 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
EXP |
Hemin results in increased expression of ACO2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases secretion |
EXP |
Hemin results in increased secretion of ADIPOQ protein |
CTD |
PMID:20016031 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases degradation |
EXP |
Hemin results in increased degradation of ALAS1 protein |
CTD |
PMID:17761694 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA] |
CTD |
PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Hemin binds to ALB protein |
CTD |
PMID:10506189 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein] |
CTD |
PMID:17541025 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
increases expression |
ISO |
Hemin results in increased expression of ARL6IP5 protein |
CTD |
PMID:16430862 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions increases expression affects localization |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BACH1 protein]; Hemin results in decreased localization of and results in decreased activity of BACH1 protein Hemin results in increased expression of BACH1 mRNA; Hemin results in increased expression of BACH1 protein Hemin affects the localization of BACH1 protein |
CTD |
PMID:18550526 PMID:31518892 PMID:33434570 PMID:36096218 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin inhibits the reaction [lead acetate results in increased expression of BAX protein] Hemin results in increased expression of BAX protein |
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Hemin results in decreased expression of BCL2 protein Hemin inhibits the reaction [lead acetate results in decreased expression of BCL2 protein] |
CTD |
PMID:27815112 PMID:29797346 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Hemin results in increased expression of BIRC2 protein |
CTD |
PMID:14647439 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased cleavage of CASP3 protein Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:17173083 PMID:18845130 PMID:19150641 PMID:19520142 PMID:26747958 PMID:27815112 PMID:31054940 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:19150641 PMID:27815112 PMID:35691465 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein] |
CTD |
PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of CDH1 mRNA |
CTD |
PMID:29269057 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein] |
CTD |
PMID:14647439 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases degradation |
ISO |
Hemin results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA] |
CTD |
PMID:29749404 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein |
CTD |
PMID:27231347 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
increases secretion multiple interactions |
ISO |
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein] |
CTD |
PMID:11232018 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]] |
CTD |
PMID:23272707 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]] |
CTD |
PMID:20188822 PMID:20837117 PMID:22120038 PMID:22159698 PMID:26747958 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]] |
CTD |
PMID:22159698 PMID:26747958 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP2B1 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP2B1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP2B1 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]] |
CTD |
PMID:11368792 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA |
CTD |
PMID:26747958 PMID:29749404 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of DLG1 protein] |
CTD |
PMID:36096218 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of EFNA1 mRNA |
CTD |
PMID:32198055 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA] |
CTD |
PMID:10381381 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
decreases expression |
ISO |
Hemin results in decreased expression of FOSL1 protein |
CTD |
PMID:20006635 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP ISO |
Hemin results in increased expression of FTH1 mRNA; Hemin results in increased expression of FTH1 protein |
CTD |
PMID:15893546 PMID:16568477 PMID:17469137 PMID:29749404 PMID:31054940 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO EXP |
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL1 mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein |
CTD |
PMID:12393473 PMID:15893546 PMID:16568477 PMID:29749404 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr17:4,482,168...4,485,153
|
|
G |
Gata1 |
GATA binding protein 1 |
increases expression decreases expression affects expression multiple interactions |
ISO |
Hemin results in increased expression of GATA1 mRNA Hemin results in decreased expression of GATA1 protein Hemin affects the expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:28552822 PMID:37329354 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression affects expression multiple interactions |
ISO |
Hemin results in decreased expression of GATA2 mRNA; Hemin results in decreased expression of GATA2 protein Hemin affects the expression of GATA2 mRNA hydroquinone affects the reaction [Hemin affects the expression of GATA2 mRNA]; hydroquinone inhibits the reaction [Hemin results in decreased expression of GATA2 protein]; hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA] |
CTD |
PMID:21414390 PMID:37329354 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GCLC mRNA; Hemin results in increased expression of GCLC protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein |
CTD |
PMID:16631525 PMID:33434570 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GCLM mRNA; Hemin results in increased expression of GCLM protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein |
CTD |
PMID:33434570 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein Hemin results in increased expression of GSR mRNA; Hemin results in increased expression of GSR protein |
CTD |
PMID:33434570 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GSTO1 mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Hemin results in increased stability of and results in increased expression of GSTP1 mRNA |
CTD |
PMID:15313425 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
decreases activity |
ISO |
Hemin results in decreased activity of GSTZ1 protein |
CTD |
PMID:1846734 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression multiple interactions decreases response to substance |
ISO |
Hemin results in increased expression of HAMP mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin] |
CTD |
PMID:29749404 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 PMID:30327826 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA |
CTD |
PMID:12393473 PMID:29749404 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression decreases expression increases activity decreases response to substance |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; BACH1 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; Hemin results in increased expression of and results in increased activity of HMOX1 protein; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein Hemin results in decreased expression of HMOX1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin |
CTD |
PMID:3343248 PMID:8764571 PMID:9337616 PMID:9722676 PMID:10349844 PMID:10473555 PMID:11232018 PMID:12051994 PMID:12393473 PMID:12690112 PMID:14563492 PMID:14647439 PMID:14871405 PMID:15316927 PMID:15589375 PMID:16109301 PMID:16462769 PMID:16631525 PMID:16647178 PMID:16839318 PMID:16959797 PMID:17173083 PMID:17204476 PMID:17275847 PMID:17420286 PMID:17464175 PMID:17541025 PMID:17979934 PMID:18206168 PMID:18215737 PMID:18357586 PMID:18550526 PMID:18845130 PMID:19080378 PMID:19136476 PMID:19190261 PMID:19520142 PMID:20016031 PMID:20638379 PMID:20961405 PMID:21525764 PMID:22859313 PMID:23272707 PMID:23942037 PMID:24095726 PMID:25268984 PMID:25449124 PMID:25824035 PMID:26747958 PMID:27777014 PMID:27815112 PMID:27830717 PMID:29086419 PMID:29749404 PMID:29797346 PMID:30040983 PMID:31054940 PMID:31518892 PMID:32671443 PMID:33434570 PMID:35691465 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases response to substance |
ISO |
HMOX2 protein results in decreased susceptibility to Hemin |
CTD |
PMID:15589375 PMID:16459095 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Hemin results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10349844 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] |
CTD |
PMID:35691465 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of IL6 mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] |
CTD |
PMID:29749404 PMID:35691465 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Fructose results in increased expression of INS protein] |
CTD |
PMID:25268984 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
EXP |
Hemin results in decreased expression of and results in decreased activity of IREB2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
Hemin results in decreased expression of IVL mRNA |
CTD |
PMID:20006635 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
ISO EXP |
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin results in decreased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein] |
CTD |
PMID:12393473 PMID:19080378 PMID:20016031 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
Hemin results in decreased expression of KEAP1 protein |
CTD |
PMID:27777014 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16959797 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein] |
CTD |
PMID:18215737 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16959797 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Hemin promotes the reaction [Paraquat results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19080378 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]] |
CTD |
PMID:27830717 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Gallic Acid results in increased activity of MGST1 protein] |
CTD |
PMID:19111564 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir126a |
microRNA 126a |
decreases expression |
ISO |
Hemin results in decreased expression of MIR126 mRNA |
CTD |
PMID:28733890 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mir451a |
microRNA 451a |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR451A mRNA hydroquinone affects the reaction [Hemin results in increased expression of MIR451A mRNA] |
CTD |
PMID:28733890 |
|
NCBI chr10:62,961,520...62,961,591
Ensembl chr10:62,961,520...62,961,591
|
|
G |
Mir486 |
microRNA 486 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR486-1 mRNA [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Hemin results in increased expression of MMP1 protein |
CTD |
PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:17979934 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA |
CTD |
PMID:12393473 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA] |
CTD |
PMID:21414390 PMID:28552822 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression affects localization decreases expression |
ISO EXP |
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; Hemin results in increased expression of and affects the localization of NFE2L2 protein; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10473555 PMID:16959797 PMID:21464371 PMID:21525764 PMID:22859313 PMID:23272707 PMID:25824035 PMID:26747958 PMID:27777014 PMID:31054940 PMID:33434570 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein] |
CTD |
PMID:14563492 PMID:15316927 PMID:26747958 PMID:27815112 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA |
CTD |
PMID:17541025 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:21464371 PMID:31054940 PMID:33434570 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of NRF1 protein] |
CTD |
PMID:30040983 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein] |
CTD |
PMID:27231347 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases expression |
EXP |
Hemin results in decreased expression of PDE5A protein |
CTD |
PMID:16839318 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein |
CTD |
PMID:20961405 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of PDGFRB mRNA |
CTD |
PMID:32198055 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases activity |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein] |
CTD |
PMID:11368792 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of PPARGC1A protein] |
CTD |
PMID:30040983 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
increases response to substance |
ISO |
PTGER2 gene mutant form results in increased susceptibility to Hemin |
CTD |
PMID:25451967 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
|